Skip to content

5-MeO-DMT: all studies

Page 68 of 112: studies 671 to 680 of 1,115, newest first. Back to the 5-MeO-DMT overview

Research

Symmetry Perception and Psychedelic Experience

Symmetry June 30, 2023 Alexis D. J. Makin, Marco Roccato, Elena Karakashevska et al. 19 citations

This review of symmetry perception has six parts. Psychophysical studies have investigated symmetry perception for over 100 years (part 1). Neuroscientific studies on symmetry perception have accumulated in the last 20 years. Functional MRI and EEG experiments have conclusively shown that regular visual arrangements, such as reflectional symmetry, Glass patterns, and the 17 wallpaper groups all...

DOI: 10.3390/sym15071340 (opens in new tab) Extrastriate cortex Symmetry geometry Reflection symmetry Visual perception +1

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

Frontiers in Psychiatry June 26, 2023 Simon Zhornitsky, Henrique Nunes Pereira Oliva, Laura A. Jayne et al. 12 citations

Background Ketamine and psychedelics have abuse liability. They can also induce “transformative experiences” where individuals experience enhanced states of awareness. This enhanced awareness can lead to changes in preexisting behavioral patterns which could be beneficial in the treatment of substance use disorders (SUDs). Preclinical and clinical studies suggest that ketamine and psychedelics...

In vivo mapping of pharmacologically induced functional reorganization onto the human brain’s neurotransmitter landscape

Science Advances June 14, 2023 Leor Roseman, Christopher Timmermann, Daniel Golkowski et al. 65 citations

To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain’s rich neurotransmitter landscape. Here, we bridge microscale molecular chemoarchitecture and pharmacologically induced macroscale functional reorganization, by relating the regional distribution of 19 neurotransmitter receptors and transporters...

DOI: 10.1126/sciadv.adf8332 (opens in new tab) Pharmacology Neurotransmitter receptor Human brain

Fungi Fiction: Analytical Investigation into the Church Of Psilomethoxin's Alleged Novel Compound Using UPLC-HRMS

ChemRxiv June 2, 2023 Samuel E. Williamson, Alexander M. Sherwood 1 citation preprint

The Church of Psilomethoxin claims to produce a novel tryptamine by adding 5-MeO-DMT to the substrate of cultivated Psilocybe mushrooms, which is then biosynthesized into psilomethoxin, the church’s sacrament. In this study, we investigate the validity of this claim using comprehensive analytical techniques, namely ultra-performance liquid chromatography with high-resolution mass spectrometry...

DOI: 10.26434/chemrxiv-2023-bxxtl-v2 (opens in new tab) Full text (opens in new tab) Psilocybin Tryptamines Context archaeology High-performance liquid chromatography +2

Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review

medRxiv June 1, 2023 Andreas Halman, Geraldine Kong, Jerome Sarris et al. 17 citations preprint

Abstract Classic psychedelics, lysergic acid diethylamide, psilocybin, mescaline and N,N-dimethyltryptamine, are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes of using these substances are used in combination with other psychoactive drugs is limited. This systematic...

In silico characterization of the psilocybin biosynthesis pathway.

Computational biology and chemistry June 1, 2023 William Irvine, Marshall Tyler, Rupika Delgoda 11 citations

Nearly all mushrooms of the Psilocybe genus contain the natural product psilocybin, which is a psychoactive alkaloid derived from l-tryptophan. Considering their use in ancient times, as well as their psychedelic properties, these mushrooms have re-emerged with psychotherapeutic potential for treating depression, which has triggered increased pharmaceutical interest. However, the psilocybin...

Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.

Psychedelic Medicine June 1, 2023 Jasper A Heinsbroek, Giuseppe Giannotti, Joel Bonilla et al. 26 citations

The potential use of psychedelic drugs as therapeutics for neuropsychiatric disorders has been limited by their hallucinogenic properties. To overcome this limitation, we developed and characterized tabernanthalog (TBG), a novel analogue of the indole alkaloids ibogaine and 5-methoxy-N,N-dimethyltryptamine with reduced cardiac arrhythmogenic risk and a lack of classical psychedelic...

Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants.

Translational Psychiatry May 23, 2023 Severin B Vogt, Laura Ley, Livio Erne et al. 85 citations

N,N-dimethyltryptamine (DMT) is distinct among classic serotonergic psychedelics because of its short-lasting effects when administered intravenously. Despite growing interest in the experimental and therapeutic use of intravenous DMT, data are lacking on its clinical pharmacology. We conducted a double-blind, randomized, placebo-controlled crossover trial in 27 healthy participants to test...

DOI: 10.1038/s41398-023-02477-4 (opens in new tab) Full text (opens in new tab) Psychedelic medicine DMT Research Clinical trials Intravenous drug administration +1

Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience

bioRxiv (Cold Spring Harbor Laboratory) May 12, 2023 S. Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al. 18 citations preprint

Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, subjective experience, and brain activity patterns. In recent work using a receptor-informed network control theory framework, we demonstrated that the serotonergic psychedelics lysergic acid diethylamide (LSD) and psilocybin flatten the brain's control energy...

Microbiome–Gut–Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders

ACS Medicinal Chemistry Letters May 11, 2023 Robert B. Kargbo 15 citations

The gut-brain axis (GBA) refers to the sophisticated bidirectional communication system connecting the digestive system with the central nervous system. This interaction is enabled by a series of intricate signaling processes, encompassing various neuro-immune and hormonal pathways. The association between the gut microbiome and mental health has garnered immense scientific and public interest,...

DOI: 10.1021/acsmedchemlett.3c00168 (opens in new tab) Full text (opens in new tab) Gut–brain axis Gut microbiome Lysergic acid Enteric nervous system +1